Chapter 1 provides new data on the latest developments in the global treatment effort, highlighting positive trends as well as aspects that require improvement. Chapter 2 summarizes the impact of the scale-up in reducing AIDS-related mortality and new HIV infections. Chapter 3 examines the sequence ...of steps in the continuum of care from HIV diagnosis to successful provision of ART services and outlines key supportive innovations. Chapter 4 discusses the implications and anticipated impact of the new "Consolidated guidelines on the use of ARV drugs for treating and preventing HIV infection
more
Aлгоритм лабораторной диагностики и мониторинга лечения туберкулеза легких и туберкулеза с лекарственной устойчивостью на основе применения современных быстрых... молекулярных методов.
Экспертное заключение членов основной группы Европейской лабораторной инициативы, подготовленное для Европейского региона ВОЗ.
more
"This Code provides practical guidance on how to manage health and safety risks associated with hazardous
chemicals for persons conducting a business or undertaking who use chemicals in their workplace."
To complement the Global Strategy progress reporting, this report provides a detailed look at country leadership and action toward the Every Newborn National Milestones by 2020. Countries have taken the initiative to show the way forward and have demonstrated significant progress. As part of monitor...ing this progress, countries have adopted the Every Newborn Tracking Tool. This report presents a compilation of the data collated by the Every Newborn Tracking Tool in 2016, when 51 countries adopted the tool; it also spotlights examples of specific country activity for each National Milestone. Finally, Global Milestones for 2020 were part of the Every Newborn Action Plan to guide global and regional work in support of country efforts and this report highlights relevant progress towards those Global Milestones.
more
BMJ 2009; 338 doi: https://doi.org/10.1136/bmj.b158 (Published 05 February 2009)
Cite this as: BMJ 2009;338:b158
Correspondence to: A Burns alistair.burns@manchester.ac.uk
Washington, D.C., EUA, del 26 al 30 de septiembre del 2016
Punto 4.10 del orden del día provisional
CD55/14 8 de julio del 2016
Original: inglés
Using the WHO model list of essential medicines to update a national essential medicines list
Since 1977, WHO has been working with countries to design the package of essential medicines as an integral component of treatment within the continuum of care, developing and disseminating the Model List ...of Essential Medicines (Model List). WHO is committed to supporting Member States in sharing best practices in selecting
essential medicines, and in developing processes for the selection of medicines for national essential medicines lists (national EMLs, or NEMLs) consistent with the evidence-based methods used for updating the WHO Model List.
more
This Key Indicators report presents selected findings of the 2019 EMDHS. A comprehensive analysis of the data will be publishedin a final report in 2019.T he primary objective of the 2019 EMDHS project is to provide up-to-date estimates of key demographic and health indicators.
IDS Rapid Response Briefing 8
Sur la base des informations disponibles au 28 février 2021
Rapid Policy Brief Series Series 14: COVID-19 and hypertension
Consultancy to conduct desk review on impact of national policies and programs on disability rights and develop an action plan to make existing policies and programs and legislation disability friendly
The purpose of this document is to offer guidance to Member States on quarantine measures for individuals in the context of COVID-19. It is intended for those responsible for establishing local or national policy for quarantine of individuals, and adherence to infection prevention and control measur...es.
more
This guidance document includes background information on Ebola virus disease, Ebola emergency committee recommendations, risks for different groups, and information for travellers from and to affected countries.